0

Close
 
Upcoming Allied Market Research
2023
Anaphylaxis Treatment Market

Anaphylaxis Treatment Market

by Drug Class (Epinephrine, Anti-Histamines, Others), by Route of Administration (Parenteral, Oral, Others) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13335
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Anaphylaxis Treatment Market

Request Now !

Anaphylaxis is a medical condition in which serious allergic conditions occur that may cause death of patient. Itchy rash, throat swelling, shortness of breath, vomiting, and low blood pressure are some symptoms of anaphylaxis. Moreover, it can cause cardiovascular, respiratory, gastrointestinal, and cutaneous manifestations result in death of patient. Insect bites, unwanted food consumption, and medication are common causes of anaphylaxis. Anaphylaxis is diagnosed on the basis of patient symptoms. Primary treatment of anaphylaxis consist of epinephrine injection into the muscle, then placing person with elevated feet to restore normal blood flow. Epinephrine auto-injector is suggested for the people who have anaphylaxis history. Other medication include anti-histamine and steroids are complementary.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the anaphylaxis treatment market.

Top Impacting Factors

  • Surge in incidence of anaphylaxis across the globe, increase in awareness regarding available treatments, rise in patients suffering from allergies, surge in geriatric population, and rise in overuse of medicines in rural areas are the key factors that drive the growth of market.
  • In addition, continuous strategic developments & promising product launches by key market players, emerging advanced technologies in developing countries, increase in demand for self-administrating treatments, R&D activities to improve quality of drugs, launch of novel drug treatment, rise in demand for cost effective treatment, and increase in demand for minimally invasive treatment can boost the growth of anaphylaxis treatment market.
  • However, lack of awareness in developing region and side effects elated to use of steroids & epinephrine can hinder the growth of market.
  • Contrarily, government initiatives to reduce cost of treatment and increase in number of product approvals are expected to offer lucrative opportunities for the expansion of the market.

Market Trend

New Product Launches to Flourish the Market

In 2020, Bausch Health announced launch of Emerade in Canada. Emerade is a 0.3mg and 0.5 mg dose auto-injector use in treatment of anaphylaxis. 

In 2019, Sandoz Inc. announced launch of SYMJEPI in U.S. This is a 0.3mg epinephrine injection for emergency treatment of allergic reaction including anaphylaxis.

In 2018, Teva Pharmaceutical received FDA approval for launch of epinephrine auto-injector. This was the first generic auto-injector equivalent to EpiPen which is an emergency injectable for anaphylaxis treatment.

Key Benefits of the Report

  • This study presents the analytical depiction of anaphylaxis treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Anaphylaxis Treatment Market Report         

  • Which are the leading players active in the anaphylaxis treatment market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "anaphylaxis treatment"?
  • What is "anaphylaxis treatment" market prediction in the future?
  • Who are the leading global players in the "anaphylaxis treatment" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "anaphylaxis treatment" market report?

 Anaphylaxis Treatment Market Report Highlights

Aspects Details
By Drug Class
  • Epinephrine
  • Anti-Histamines
  • Others
By Route of Administration
  • Parenteral
  • Oral
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Lincoln Medical Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Adamis Pharmaceutical Corporation, Impax Laboratories Inc., Pfizer Inc, Mylan N.V., ALK-Abelló., MannKind Corporation, GlaxoSmithKline Plc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. Epinephrine

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Anti-Histamines

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Parenteral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Oral

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ANAPHYLAXIS TREATMENT MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drug Class

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Anaphylaxis Treatment Market

        • 7.2.6.1. Market Size and Forecast, By Drug Class
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Anaphylaxis Treatment Market

        • 7.2.7.1. Market Size and Forecast, By Drug Class
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Anaphylaxis Treatment Market

        • 7.2.8.1. Market Size and Forecast, By Drug Class
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drug Class

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Anaphylaxis Treatment Market

        • 7.3.6.1. Market Size and Forecast, By Drug Class
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Anaphylaxis Treatment Market

        • 7.3.7.1. Market Size and Forecast, By Drug Class
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Anaphylaxis Treatment Market

        • 7.3.8.1. Market Size and Forecast, By Drug Class
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Anaphylaxis Treatment Market

        • 7.3.9.1. Market Size and Forecast, By Drug Class
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Anaphylaxis Treatment Market

        • 7.3.10.1. Market Size and Forecast, By Drug Class
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Anaphylaxis Treatment Market

        • 7.3.11.1. Market Size and Forecast, By Drug Class
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Anaphylaxis Treatment Market

        • 7.3.12.1. Market Size and Forecast, By Drug Class
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drug Class

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Anaphylaxis Treatment Market

        • 7.4.6.1. Market Size and Forecast, By Drug Class
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Anaphylaxis Treatment Market

        • 7.4.7.1. Market Size and Forecast, By Drug Class
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Anaphylaxis Treatment Market

        • 7.4.8.1. Market Size and Forecast, By Drug Class
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Anaphylaxis Treatment Market

        • 7.4.9.1. Market Size and Forecast, By Drug Class
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Anaphylaxis Treatment Market

        • 7.4.10.1. Market Size and Forecast, By Drug Class
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Anaphylaxis Treatment Market

        • 7.4.11.1. Market Size and Forecast, By Drug Class
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Anaphylaxis Treatment Market

        • 7.4.12.1. Market Size and Forecast, By Drug Class
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Anaphylaxis Treatment Market

        • 7.4.13.1. Market Size and Forecast, By Drug Class
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Anaphylaxis Treatment Market

        • 7.4.14.1. Market Size and Forecast, By Drug Class
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drug Class

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Anaphylaxis Treatment Market

        • 7.5.6.1. Market Size and Forecast, By Drug Class
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Anaphylaxis Treatment Market

        • 7.5.7.1. Market Size and Forecast, By Drug Class
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Anaphylaxis Treatment Market

        • 7.5.8.1. Market Size and Forecast, By Drug Class
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Anaphylaxis Treatment Market

        • 7.5.9.1. Market Size and Forecast, By Drug Class
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Anaphylaxis Treatment Market

        • 7.5.10.1. Market Size and Forecast, By Drug Class
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Anaphylaxis Treatment Market

        • 7.5.11.1. Market Size and Forecast, By Drug Class
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Impax Laboratories Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Lincoln Medical Ltd.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Mylan N.V.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Adamis Pharmaceutical Corporation

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. MannKind Corporation

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Pfizer Inc

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. GlaxoSmithKline Plc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Merck And Co., Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Teva Pharmaceutical Industries Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. ALK-Abelló.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR EPINEPHRINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR ANTI-HISTAMINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ANAPHYLAXIS TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL ANAPHYLAXIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ANAPHYLAXIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE ANAPHYLAXIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. ITALY ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 38. ITALY ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. UK ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. UK ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. UK ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC ANAPHYLAXIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. INDIA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. INDIA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA ANAPHYLAXIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 96. UAE ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 97. UAE ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. UAE ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA ANAPHYLAXIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA ANAPHYLAXIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA ANAPHYLAXIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. IMPAX LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 106. IMPAX LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 107. IMPAX LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 108. IMPAX LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 109. IMPAX LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. LINCOLN MEDICAL LTD.: KEY EXECUTIVES
  • TABLE 111. LINCOLN MEDICAL LTD.: COMPANY SNAPSHOT
  • TABLE 112. LINCOLN MEDICAL LTD.: OPERATING SEGMENTS
  • TABLE 113. LINCOLN MEDICAL LTD.: PRODUCT PORTFOLIO
  • TABLE 114. LINCOLN MEDICAL LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 116. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 117. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 118. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 119. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. ADAMIS PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
  • TABLE 121. ADAMIS PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 122. ADAMIS PHARMACEUTICAL CORPORATION: OPERATING SEGMENTS
  • TABLE 123. ADAMIS PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 124. ADAMIS PHARMACEUTICAL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. MANNKIND CORPORATION: KEY EXECUTIVES
  • TABLE 126. MANNKIND CORPORATION: COMPANY SNAPSHOT
  • TABLE 127. MANNKIND CORPORATION: OPERATING SEGMENTS
  • TABLE 128. MANNKIND CORPORATION: PRODUCT PORTFOLIO
  • TABLE 129. MANNKIND CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. PFIZER INC: KEY EXECUTIVES
  • TABLE 131. PFIZER INC: COMPANY SNAPSHOT
  • TABLE 132. PFIZER INC: OPERATING SEGMENTS
  • TABLE 133. PFIZER INC: PRODUCT PORTFOLIO
  • TABLE 134. PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 136. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 137. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 138. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 139. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 141. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 142. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 143. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 144. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 146. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 147. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 148. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 149. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. ALK-ABELLó.: KEY EXECUTIVES
  • TABLE 151. ALK-ABELLó.: COMPANY SNAPSHOT
  • TABLE 152. ALK-ABELLó.: OPERATING SEGMENTS
  • TABLE 153. ALK-ABELLó.: PRODUCT PORTFOLIO
  • TABLE 154. ALK-ABELLó.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANAPHYLAXIS TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANAPHYLAXIS TREATMENT MARKET
  • FIGURE 3. SEGMENTATION ANAPHYLAXIS TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANAPHYLAXIS TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANAPHYLAXIS TREATMENT MARKET
  • FIGURE 11. ANAPHYLAXIS TREATMENT MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. ANAPHYLAXIS TREATMENT MARKET FOR EPINEPHRINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ANAPHYLAXIS TREATMENT MARKET FOR ANTI-HISTAMINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ANAPHYLAXIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ANAPHYLAXIS TREATMENT MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 16. ANAPHYLAXIS TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. ANAPHYLAXIS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ANAPHYLAXIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ANAPHYLAXIS TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 20. ANAPHYLAXIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. ANAPHYLAXIS TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. ANAPHYLAXIS TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: ANAPHYLAXIS TREATMENT MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. IMPAX LABORATORIES INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. IMPAX LABORATORIES INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. IMPAX LABORATORIES INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. LINCOLN MEDICAL LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. LINCOLN MEDICAL LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. LINCOLN MEDICAL LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. MYLAN N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. MYLAN N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ADAMIS PHARMACEUTICAL CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ADAMIS PHARMACEUTICAL CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ADAMIS PHARMACEUTICAL CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. MANNKIND CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. MANNKIND CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. MANNKIND CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. PFIZER INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. PFIZER INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. PFIZER INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. ALK-ABELLó.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. ALK-ABELLó.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. ALK-ABELLó.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Anaphylaxis Treatment Market

Start reading.
This Report and over 66,944+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers